Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Active charcoal combined with zhubarb containing preparation as an adjuvant measure to control hyperphosphatemia in patients on dialysis

Oral activated charcoal decreases serum phosphate level and calcium phosphorus products in dialysis patients with refractory hyperphosphataemia

Lanthanum Carbonate for the Treatment of Hyperphosphatemia in Ckd 5d: Multicenter, Double Blind, Randomized, Controlled Trial in Mainland China

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Clinical Research of Hemodialysis Combined with Colon Dialysis in Uremic Patients with Hyperphosphatemia

Mineral and Bone Disorder in Chinese Dialysis Patients: a Multicenter Study

Effect of Short-Term Low-Protein Diet Supplemented with Keto Acids on Hyperphosphatemia in Maintenance Hemodialysis Patients

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

In vitro phosphate-binding ability of calcium-based agents is augmented by co-administration of activated charcoal.

Multicenter Randomized Controlled Clinical Trial of Medicinal Charcoal in the Treatment of Chronic Renal Insufficiency

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study.

Tolerability, Safety and Efficacy of a Novel Phosphate Binder VS-505 (AP301): a Phase 2 Dose-Escalation and Dose-Ranging Study in Patients Undergoing Maintenance Hemodialysis.

Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients

Calcium polystyrene sulfonate in treating hyperkalemia patients with chronic kidney disease: a multi-center clinical study

Efficacy and Safety of Polysaccharide Iron Complex Capsules Compared with Iron Sucrose in Hemodialysis Patients: Study Protocol for a Randomized, Open-Label, Positive Control, Multicenter Trial (IHOPE)

Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia

P1576THE EFFECT OF CHANGING DIETARY PHOSPHORUS-PROTEIN RATIO ON NUTRITIONAL STATUS OF HEMODIALYSIS PATIENTS

Clinical effect of rhubarb on the treatment of chronic renal failure: A meta-analysis

Short-term efficacy of sevelamer hydrochloride on hyperphosphatemia in patients undergoing maintenance hemodialysis

Association of adequate dietary phosphate restriction education and phosphorus management in maintenance hemodialysis patients

Calcium and Phosphonium Metabolism in Peritoneal Dialysis Patients with Different Dialysates